



APPENDIX

Biomarkers levels of anemia and iron metabolism in Coronavirus disease 2019: A systematic review and meta-analysis


Supplemental figure S1. Meta-analysis of mean hemoglobin levels in COVID-19 patients



Supplemental figure S2. Meta-analysis of differences in mean hemoglobin(a) and ferritin (b) levels between severe and moderate COVID-19 patients




a




b

Supplemental figure S3. Meta-analysis of differences in mean hemoglobin (a) and ferritin (b) levels between deceased and COVID-19 patients who survived





a




b


Supplemental figure S4. Meta-analysis of mean ferritine levels in COVID-19 adult and pediatric patients, and in adult only.






Supplemental figure S5. Bubble plots on mean hemoglobin levels by age, percentage of patients survived, percentage of male population, percentage of patients at intensive care, percentage of patients with cardiovascular diseases, hypertension and type 2 diabetes



Supplemental figure S6. Bubble plots on weighted mean difference in hemoglobin levels between severe vs moderate Covid-19 cases by age, percentage of male population, percentage of patients at intensive care




Supplemental figure S7. Bubble plots on mean ferritin levels by age and percentage of male patients overall (a) and including paediatric population (b), mean percentage of patients with hypertension (c) mean ferritin levels by mean haemoglobin levels (d)




Supplemental figure S8. Publication bias for the meta-analysis on differences in mean hemoglobin levels between severe and moderate COVID-19 patients (a) and between deceased and survived Covid-19 cases (b)

a)



b)



Supplemental table S1. Characteristics of studies included in current review

DOI	Author name	Study Design	No. of individuals	Study location	Mean Age (SD)	Pediatric/Adult/Mix population	Percentage of males(n%)	Survival	Percentages of individuals with comorbidities	Ferritin	Hemoglobin	Study Quality
10.1136/bmj.m1092	Chen et al.	Retrospective study	274	China	58,6 (19,4)	Adult	62,40	58,7	49	x	x	8
10.1016/S0140-6736(20)30211-7	Chen et al.	Descriptive study	99	China	55,5 (13,1)	Adult	68	89,0	51	x	x	7
10.1172/JCI137244	Chen et al.	Retrospective study	21	China	57,0 (11,9)	Adult	81	80,9	38,1	x	x	7
10.1016/j.kint.2020.03.005	Cheng et al.	Prospective cohort study	701	China	61,3 (15,6)	Adult	52,4	83,9	42,60		x	8
10.1007/s15010-020-01427-2	Du et al.	Retrospective study	67	China	24,7 (7,2)	Mix	47,8	100	N/A		x	8
10.1164/rccm.202003-0543OC	Du et al.	Retrospective study	85	China	57,9 (21,1)	Mix	72,90	0	68,20		x	6
10.1164/rccm.202002-0445OC	Feng et al.	Multi-center retrospective study	476	China	52,3 (17,8)	Mix	56,90	92	43,10		x	8
10.1056/NEJMoa2002032	Guan et al.	Cross-sectional	1099	China	46,7 (17,1)	Mix	58,10	98,6	23,70		x	8
10.1007/s11427-020-1661-4	Hu et al.	Cross-sectional	24	China	35,00 (10,98)	Mix	33,30	100	N/A		x	6
10.1016/S0140-6736(20)30183-5	Huang et al.	Prospective	41	China	49,25 (4,91)	Adult	73,00	85	32,00		x	8
10.1016/j.tmaid.2020.101606	Huang et al.	Retrospective	34	China	56,24 (1,14)	Adult	41,20	99,85	47,10		x	6

10.1136/gutjnl-2020-320926	Jin et al.	Retrospective	651	China	45,20 (14,43)	Adult	50,84	90,76	27,34		x	8
10.1016/j.tmaid.2020.101664	Lei et al.	Cross-sectional	119	China	53,4 (13,3)	Adult	64,70	0	47,80		x	7
10.1016/j.ijid.2020.03.053	Li et al.	Retrospective	25	China	75,25 (12,99)	Adult	40,00	100	100		x	6
10.1016/j.jaci.2020.04.006	Li et al.	Prospective	548	China	59,25 (6,06)	Adult	50,90	94,65	64,40	x		9
10.1093/cid/ciaa242	Lian et al.	Retrospective	788	China	45,83 (10,79)	Mix	51,70	86,53	27,60		x	8
10.1016/j.jinf.2020.03.005	Liu et al.	Cross-sectional	56	China	52,48 (3,68)	Adult	55,35	100	N/A		x	8
10.1016/j.jinf.2020.04.002	Liu et al.	Retrospective	245	China	53,95 (16,90)	Adult	46,53	85	N/A		x	8
10.14309/ajg.0000000000000620	Pan L et al.	Cross-sectional study	204	China	52,91 (15,98)	Adult	52,45	17,65	N/A		x	8
10.1002/ctm2.23.	Pan Y et al.	Case-controls study	84	China	58,6 (15,6)	Adult	60,71	N/A	N/A		x	7
10.1016/j.jcv.2020.104353	Tan et al.	Retrospective study	10	China	7,1 (3,6)	Pediatric	30,0	100	0	x		6
10.1016/j.ijid.2020.03.070	Wang et al.	Retrospective cohort	125	China	38,76 (13,7)	Mix	56,8	N/A	27,20		x	6
10.1016/j.jinf.2020.03.019	Wang L et al.	Retrospective cohort	339	China	70 (8,18)	Adult	49	80,82	N/A		x	8
10.1093/cid/ciaa272	Wang Z et al.	Retrospective cohort	69	China	46,33 (20,44)	Mix	46	7,5	N/A		x	7
10.1001/jamainternmed.2020.0994	Wu C et al.	Retrospective cohort	201	China	51,3 (12,6)	Mix	63,7	78,1	32,8	x		6
10.1093/cid/ciaa199	Wu J et al.	Cross-sectional study	80	China	46,1 (15,42)	Mix	48,75	100	47,50		X	7

10.1016/S2213-2600(20)30079-5	Yang X et al.	Retrospective cohort	52	China	51,9 (12,9)	Adult	67	38,4	40		x	8
10.1001/jama.2020.3204	Young B et al.	Cross-sectional study	18	Singapore	50,33 (33,78)	Mix	50	100	28		x	6
10.1016/j.ijid.2020.03.040	Zhang X et al.	Retrospective cohort	645	China	43,12 (13,91)	Mix	50,85	100	27,44		x	8
10.26355/eurrev_202003_20711	Zheng et al.	Retrospective cohort	161	China	45 (17,5)	Adult	49,7	N/A	20,5		x	7
10.1016/S0140-6736(20)30566-3	Zhou et al.	Retrospective cohort	191	China	56 (15,68)	Adult	119,62	71,27	48	x	x	8
10.1001/jama.2020.6775	Richardson et al.	Descriptive study	4,344	USA	63.3	Mix	60.3	93.9	N/A	x		9
10.1515/dx-2020-0046	Aggarwal et al.	Retrospective	16	USA	66,75 (16,45)	Adult	75,00	81,25	N/A		x	7
10.1016/j.gendis.2020.03.008	Chen et al.	Cross-sectional	12	China	13,50 (1,86)	Pediatric	50,00	100	N/A		x	7
10.1007/s15010-020-01432-5	Chen et al.	Retrospective	145	China	47,50 (14,60)	Adult	54,48	100	N/A		x	8
10.1002/ajh.25774	Fan et al.	Cross-sectional	67	Singapore	43,25 (5,49)	Adult	55,20	100	N/A		x	8
10.1002/dmrr.3319	Guo et al.	Retrospective	174	China	58,50 (5,18)	Adult	43,70	94,8	N/A	x	x	8
10.1016/j.numecd.2020.04.013	Li et al.	Retrospective	83	China	45 (8,62)	Adult	41,00	92,8	N/A	x	x	9
10.1038/s41374-020-0431-6	Li et al.	Retrospective	54	China	61,8 (14,5)	Adult	63,00	88,9	55,60	x		7
10.1007/s11596-020-2176-2	Li et al.	Retrospective	25	China	48,48 (7,70)	Adult	48,00	80	N/A	x		8

10.1038/s41430-020-0642-3	Li et al.	Cross-sectional	182	China	68,50 (8,80)	Adult	35,71	N/A	N/A		x	9
10.1016/j.ebiom.2020.102763	Liu et al.	Retrospective	40	China	48,70 (13,90)	Adult	37,50	92,5	35,00	x	x	8
10.4158/EP-2020-0108	Wang F et al	Retrospective	28	Wuhan, China	68,6 (9,0)	Adult	75,00	57,10	100,00	x	x	8
10.1172/jci.insight.137799	Wang F et al	Prospective	65	Wuhan, China	57,11 (13,03)	Adult	57,00	92	N/A	x	x	8
10.2147/CLEP.S249903	Wang L et al	Cross-sectional	26	Wuhan, China	42,93 (15,52)	Adult	42,30	N/A	N/A		x	6
10.1002/jmv.25930	Xie J et al	Cross-sectional	56	Wuhan, China	56,83 (11,79)	Adult	68,00	N/A	25,00		x	6
10.1002/jmv.25944	Xu T et al	Retrospective	15	China	26,66 (15,54)	Mixed	66,70	100	20,00		x	7
10.1136/bmjdr-2020-001343	Yan Y et al	Retrospective	193	Wuhan, China	62 (17,93)	Adult	59,10	60	48,70	x	x	8
10.20452/pamw.15312	Yao Q et al	Retrospective	108	China	49 (15,78)	Adult	39,80	89	23,10	x		8
10.1016/j.clinthera.2020.04.009	Yu T et al	Cross-sectional	95	China	38,31 (17,19)	Adult	55,80	N/A	N/A		x	8
10.1080/09537104.2020.1754383	Liu et al.	Retrospective cohort study	383	China	47,0 (20,1)	Adult	42,30	87,2	N/A		x	9
10.1371/journal.ppat.1008520	Meng et al.	Retrospective study	168	China	56,7 (15,1)	Adult	51,20	86,60	33,90	x	x	9
10.1016/j.jcrc.2020.04.004	Piva et al.	single-center cohort study	33	Italy	65 (10,1)	Adult	93,90	97,0	N/A		x	7
10.1016/j.jaut.2020.102473	Sun et al.	Retrospective study	63	China	45,5 (17,6)	Mix	58,70	100	46		x	8
10.1016/j.cca.2020.04.024	Sun et al.	Retrospective study	116	China	49,3 (12,01)	Adult	51,70	100	N/A		x	7

10.1111/cts.12805	Zhou et al.	Retrospective study	21	China	66,1 (13,94)	Adult	61,9	85,70	76,20		x	6
-------------------	-------------	---------------------	----	-------	-----------------	-------	------	-------	-------	--	---	---

Supplementary Table S2. Subgroup analyses					
Subgroups by study characteristics		Number of studies	Mean (95 % CI)	I ² for heterogeneity	P value for heterogeneity (meta-regression)
Mean serum total hemoglobin, g/L					
^a Median age, y	≤50.33	25	133.33 (131.20; 135.45)	97.6%	0.001
	>50.33	24	127.15 (125.13;129.17)	98.3%	
Median percentage of male population, %	≤54.48	25	130.41(128.42;132.39)	98.8%	0.33
	>54.48	24	131.33 (128.85;133.81)	94.7%	
Median percentage of population with comorbidities, % ¹	≤39.05	16	126.400 122.247 130.553	97.2%	0.04
	>39.05	14	128.620 126.846 130.394	81.5%	
Median percentage of population with cardiovascular diseases, % ¹	≤8	16	130.88 (128.12; 133.65)	98.7%	0.17
	>8	15	127.53 (124.29; 130.78)	95.3%	
Median percentage of population with hypertension, % ¹	≤21.1	17	130.67 (127.89; 133.45)	98.4%	0.35
	>21.1	17	132.37 (128.98; 135.76)	92.2%	
Median percentage of population with type 2 diabetes, % ¹	≤11.5	19	132.30 (130.01; 134.6)	92.8%	0.01
	>11.5	17	126.46 (124.23; 128.69)	97.7%	
Population	Adult	33	129.15(126.58; 131.712)	98.3%	0.04

	Adult and pediatric	15	133.59(131.04; 136.14)	95%	
Median percentage of population at ICU, % ¹	≤15.64	19	135.25 (133.29;137.20)	96.4%	0.001
	>15.64	18	128.88 (126.66;131.10)	89.2%	
Median percentage of population survived at the end of the study, % ¹	≤90.76	14	129.08 (127.45;130.71)	84.5%	0.17
	>90.76	13	132.08(128.78;135.38)	99%	
¹ information was not available for every study					

Supplementary Table S3. Subgroup analyses					
Subgroups by study characteristics		Number of studies	Mean (95 % CI)	I^2 for heterogeneity	P value for heterogeneity (meta-regression)
Mean serum total Ferritin, ng/L					
^a Median age, y	≤56.7	5	692.92 (449.81;936.03)	97.8%	0.59
	>56.37	5	805.43 (460.51; 1150.35)	99.6%	
Median percentage of male population, %	≤62.4	5	653.529 382.685 924.372	99.6%	0.25
	>62.4	4	801.191 718.359 884.023	41.4%	
Median percentage of population with comorbidities, % ¹			NA		
			NA		
Median percentage of population with cardiovascular diseases, % ¹			NA		
			NA		
Median percentage of population with hypertension, % ¹	27.35%	4	702.693 457.949 947.437	96.5%	0.89
	27.35%	3	736.672 392.191 1081.154	99.5%	
Population	Adult		838.46 (780.32; 896.59)	0%	0.12
	Adult and pediatric		628.72 (360.04; 897.41)	99-6%	
Median percentage of population at ICU, % ¹			NA		

			NA		
Median percentage of population survived at the end of the study, % ¹			NA		
			NA		
¹ information was not available for sufficient number of study (n=8)					

Supplementary Table S4. Subgroup analyses					
Subgroups by study characteristics		Number of studies	Mean (95 % CI)	² I ² for heterogeneity	³ P value for heterogeneity (meta-regression)
Mean difference in total hemoglobin, g/L (severe vs moderate cases)					
^a Median age, y	≤49	10	-3.28 (-5.14; -1.43)	0%	0.88
	>49	9	-4.13 (-9.1; 0.83)	79.2%	
Median percentage of male population, %	≤56.9	7	-5.30 (-7.18; -3.43)	0%	0.58
	>56.9	9	-3.34 (-8.14 ; 1.46)	80.4%	
Median percentage of population with comorbidities, % ¹	≤32	11	-3.35 (-6.47; -0.24)	73.7%	0.22
	>32	5	-8.44 (-11.51; -5.37)	0%	
Population	Adult	12	-3.58 (-7.24; 0.07)	69.2%	0.62
	Adult and pediatric	7	-4.86 (-8.04; -1.68)	51.8%	
Median percentage of population at ICU, %	≤18.95	12	-2.62 (-5.41; 0.16)	52%	0.04
	>18.95	7	-8.03 (-9.95; -6.12)	0%	
Median percentage of population survived at the end of the study, % ²	≤90.76	NA	NA	NA	
	>90.76	NA	NA	NA	
¹ information was not available for every study					

2 in total, 9 studies provided necessary information, therefore we could not perform subgroup analysis

Supplemental Table S4. Study Quality Assessment

Author-Journal	Selection	Comparability	Outcome	Total	Comments
Chen-JCI (1)	3	1	3	7	Retrospective assessment in a single center study, SARS COV2 positive only
Chen-Lancet (2)	3	1	3	7	Retrospective single center
Chen-BMJ (3)	4	1	3	8	Single center cohort
Cheng-KI (4)	3	2	3	8	3 centers
Du-Infection (5)	4	1	3	8	2 centers, restrospective
Du-AJRCCM (6)	3	1	2	6	2 centers retrospective, only included mortalities
Feng-AJRCCM (7)	4	1	3	8	3 center study restrospective, all spectrum of cases
Guan-NEJM (8)	4	2	2	8	552 centers (Largest study?)
Hu-SCLF (9)	3	1	2	6	Only asymptomatic, restrospective study from screening centers
Huang-Lancet (10)	4	1	3	8	Outbreak investigation, retrospective study
Huang-TMID (11)	3	1	2	6	CS study on Editorial Letter format. No details on methods. Single center

Jin-Gut (12)	3	2	3	8	Few details on the recruitment of participants, retrospective data
Lei-TMID (13)	3	1	3	7	Cross sectional study, single center
Li-IJID (14)	3	1	2	6	Single center, only mortalities are included
Li-JACI (15)	4	2	3	9	Ambispective cohort analysis
Lian-CID (16)	3	2	3	8	Analysis on elderly vs non-elderly outcomes
Liu-JI (17)	3	2	3	8	Restrospective analysis, single center, with age stratified analysis
Liu-JI (18)	3	2	3	8	Single center, retrospective analysis, with analysis on biomarkers and risk factors
Pan-AJG (19)	3	2	3	8	CS, 3 centers, random selection of 310 patients from participating centers
Pan-CTM (20)	3	1	3	7	3 centers, random selection of participants, predictive acuity of routine tests
Tan-JCV (21)	3	1	2	6	COVID in children, single center, small sample size
Wang-JI (22)	3	2	3	8	Only included elderly, single center, only in severe

Wang-IJID (23)	3	1	2	6	Purely descriptive study,
Wang-CID (24)	3	1	3	7	Single center, only admitted patient
Wu-JAMA (25)	3	1	3	7	Single center, confirmed cases, Comparison on ARDS/death study
Wu-CID (26)	3	1	2	6	Multicenter, retrospective, study outside Wuhan
Yang-NEJM (27)	3	2	3	8	Single center, only critically ill patients
Young-JAMA (28)	3	1	2	6	Outbreak response in Singapore , purely descriptive study
Zhang-IJID (29)	3	2	3	8	Focus on radiologic analysis
Zheng-ERMPS (30)	3	1	3	7	Single center retrospective data collection on confirmed cases
Zhou-NEJM (31)	3	2	3	8	Retrospective cohort, only adults with confirmed case, 2 centers
Wang-EP (32)	3	2	3	8	Study limited only to diabetes
Wang-CE (33)	3	2	3	8	Limited to patient transmission
Wang-JCI (34)	3	1	2	6	Laboratory assay of 65 COVID patients focusing on immunity
Xie-JMV (35)	3	1	2	6	Validation of an IgG-IgM test using 56 patients

Xu-JMV (36)	3	2	2	7	Focus on asymptomatic cases and clinical trajectory
Yan-BMJO (37)	3	2	3	8	Study on patients with diabetes, single center observational study
Yu-CT (38)	3	2	3	8	Cross sectional multicenter, to determine risk factors for severe disease
Yao-PAIM (39)	3	2	3	8	Retrospective review on severe cases
Aggarwal (40)	3	1	3	7	Single center retrospective data collection on confirmed cases
Chen (41)	3	1	3	7	Cross-sectional study, limited data
Chen (42)	4	1	3	8	Retrospective data of 145 patients
Fan (43)	4	1	3	8	Data of National Centre for Infectious Diseases (NCID)
Guo (44)	3	2	3	8	Study limited only to diabetes
Li (45)	4	2	3	9	Study limited only to CVD
Li (46)	3	1	3	7	Single center retrospective data collection on confirmed cases
Li (47)	3	2	3	8	Data from a single thoracic department
Li (48)	4	2	3	9	182 elderly patients

Liu (49)	3	2	3	8	Retrospective single center study
Sun (50)	3	2	2	7	Retrospective study
Sun (51)	3	2	3	8	Retrospective study
Piva (52)	3	2	2	7	Single-center observational cohort study
Meng (53)	3	3	3	9	Retrospective study of severe and critically ill patients
Liu (54)	3	3	3	9	Retrospective cohort study
Zhou (55)	2	2	2	6	Retrospective study of severe and critically ill patients
Richardson (56)	4	3	3	10	Retrospective analysis of sequentially hospitalized patients

1. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. *The Journal of clinical investigation*. 2020.
2. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *The Lancet*. 2020;395(10223):507-13.
3. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ (Clinical research ed)*. 2020;368:m1091.
4. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. *Kidney International*. 2020;20:20.
5. Du W, Yu J, Wang H, Zhang X, Zhang S, Li Q, et al. Clinical characteristics of COVID-19 in children compared with adults in Shandong Province, China. *Infection*. 2020.
6. Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, et al. Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan: A Retrospective Observational Study. *American journal of respiratory and critical care medicine*. 2020.
7. Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with Different Severity: A Multi-center Study of Clinical Features. *American journal of respiratory and critical care medicine*. 2020.
8. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *The New England journal of medicine*. 2020.

9. Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. *Science China Life sciences*. 2020.
10. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet*. 2020;395(10223):497-506.
11. Huang Y, Tu M, Wang S, Chen S, Zhou W, Chen D, et al. Clinical characteristics of laboratory confirmed positive cases of SARS-CoV-2 infection in Wuhan, China: A retrospective single center analysis. *Travel Medicine and Infectious Disease*. 2020.
12. Jin X, Lian JS, Hu JH, Gao J, Zheng L, Zhang YM, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. *Gut*. 2020.
13. Lei Z, Cao H, Jie Y, Huang Z, Guo X, Chen J, et al. A cross-sectional comparison of epidemiological and clinical features of patients with coronavirus disease (COVID-19) in Wuhan and outside Wuhan, China. *Travel Medicine and Infectious Disease*. 2020:101664.
14. Li X, Wang L, Yan S, Yang F, Xiang L, Zhu J, et al. Clinical characteristics of 25 death cases with COVID-19: a retrospective review of medical records in a single medical center, Wuhan, China. *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases*. 2020.
15. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. *J Allergy Clin Immunol*. 2020.
16. Lian J, Jin X, Hao S, Cai H, Zhang S, Zheng L, et al. Analysis of Epidemiological and Clinical features in older patients with Corona Virus Disease 2019 (COVID-19) out of Wuhan. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2020.
17. Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients. *Journal of Infection*. 2020.
18. Liu Y, Du X, Chen J, Jin Y, Peng L, Wang HHX, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. *J Infect*. 2020.
19. Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, et al. Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study. *Am J Gastroenterol*. 2020.
20. Pan Y, Ye G, Zeng X, Liu G, Zeng X, Jiang X, et al. Can routine laboratory tests discriminate SARS-CoV-2 infected pneumonia from other causes of community acquired pneumonia? *Clinical and Translational Medicine*. 2020.
21. Tan YP, Tan BY, Pan J, Wu J, Zeng SZ, Wei HY. Epidemiologic and clinical characteristics of 10 children with coronavirus disease 2019 in Changsha, China. *Journal of Clinical Virology*. 2020;127.
22. Wang L, He W, Yu X, Hu D, Bao M, Liu H, et al. Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up. *Journal of Infection*. 2020.
23. Wang R, Pan M, Zhang X, Fan X, Han M, Zhao F, et al. Epidemiological and clinical features of 125 Hospitalized Patients with COVID-19 in Fuyang, Anhui, China. *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases*. 2020.
24. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2020.
25. Wu C CC, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Internal Medicine*. 2020.
26. Wu J, Liu J, Zhao X, Liu C, Wang W, Wang D, et al. Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2020.

27. Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. 2020.
28. Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, et al. Epidemiologic Features and Clinical Course of Patients Infected with SARS-CoV-2 in Singapore. *JAMA - Journal of the American Medical Association*. 2020.
29. Zhang X, Cai H, Hu J, Lian J, Gu J, Zhang S, et al. Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings. *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases*. 2020.
30. Zheng F, Tang W, Li H, Huang YX, Xie YL, Zhou ZG. Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha. *European Review for Medical and Pharmacological Sciences*. 2020;24(6):3404-10.
31. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*. 2020.
32. Wang F, Yang Y, Dong K, Yan Y, Zhang S, Ren H, et al. Clinical Characteristics of 28 Patients with Diabetes and Covid-19 in Wuhan, China. *Endocr Pract*. 2020.
33. Wang L, Duan Y, Zhang W, Liang J, Xu J, Zhang Y, et al. Epidemiologic and Clinical Characteristics of 26 Cases of COVID-19 Arising from Patient-to-Patient Transmission in Liaocheng, China. *Clin Epidemiol*. 2020;12:387-91.
34. Wang F, Hou H, Luo Y, Tang G, Wu S, Huang M, et al. The laboratory tests and host immunity of COVID-19 patients with different severity of illness. *JCI Insight*. 2020.
35. Xie J, Ding C, Li J, Wang Y, Guo H, Lu Z, et al. Characteristics of patients with coronavirus disease (COVID-19) confirmed using an IgM-IgG antibody test. *Journal of Medical Virology*. 2020.
36. Xu T, Huang R, Zhu L, Wang J, Cheng J, Zhang B, et al. Epidemiological and clinical features of asymptomatic patients with SARS-CoV-2 infection. *Journal of Medical Virology*. 2020.
37. Yan Y, Yang Y, Wang F, Ren H, Zhang S, Shi X, et al. Clinical characteristics and outcomes of patients with severe covid-19 with diabetes. *BMJ Open Diabetes Research & Care*. 2020;8(1).
38. Yu T, Cai S, Zheng Z, Cai X, Liu Y, Yin S, et al. Association Between Clinical Manifestations and Prognosis in Patients with COVID-19. *Clin Ther*. 2020.
39. Yao Q, Wang P, Wang X, Qie G, Meng M, Tong X, et al. Retrospective study of risk factors for severe SARS-Cov-2 infections in hospitalized adult patients. *Pol Arch Intern Med*. 2020.
40. Aggarwal, S., Garcia-Telles, N., Aggarwal, G., Lavie, C., Lippi, G., & Henry, B. (2020). Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): Early report from the United States, *Diagnosis*, 7(2), 91-96.
41. Chen, J., Zhang, Z. Z., Chen, Y. K., Long, Q. X., Tian, W. G., Deng, H. J., ... & Hu, P. (2020). The clinical and immunological features of pediatric COVID-19 patients in China. *Genes & Diseases*.
42. Chen, Q., Zheng, Z., Zhang, C. et al. Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19) in Taizhou, Zhejiang, China. *Infection* (2020).
43. Fan, B. E., Chong, V. C. L., Chan, S. S. W., Lim, G. H., Lim, K. G. E., Tan, G. B., ... & Ong, K. H. (2020). Hematologic parameters in patients with COVID-19 infection. *American journal of hematology*.
44. Guo, W., Li, M., Dong, Y., Zhou, H., Zhang, Z., Tian, C., ... & Zhao, L. (2020). Diabetes is a risk factor for the progression and prognosis of COVID-19. *Diabetes/metabolism research and reviews*.
45. Li, M., Dong, Y., Wang, H., Guo, W., Zhou, H., Zhang, Z., ... & Zhao, L. (2020). Cardiovascular disease potentially contributes to the progression and poor prognosis of COVID-19. *Nutrition, Metabolism and Cardiovascular Diseases*.
46. Li, Y., Hu, Y., Yu, J. et al. Retrospective analysis of laboratory testing in 54 patients with severe- or critical-type 2019 novel coronavirus pneumonia. *Lab Invest* (2020).

47. Li, Y., Peng, S., Li, L. et al. Clinical and Transmission Characteristics of Covid-19 — A Retrospective Study of 25 Cases from a Single Thoracic Surgery Department. *CURR MED SCI* 40, 295–300 (2020). <https://doi.org/10.1007/s11596-020-2176-2>
48. Li, T., Zhang, Y., Gong, C. et al. Prevalence of malnutrition and analysis of related factors in elderly patients with COVID-19 in Wuhan, China. *Eur J Clin Nutr* (2020).
49. Liu, J., Li, S., Liu, J., Liang, B., Wang, X., Wang, H., ... & Xiong, L. (2020). Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. *EBioMedicine*, 102763.
50. Sun, S., Cai, X., Wang, H., He, G., Lin, Y., Lu, B., ... & Hu, X. (2020). Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China. *Clinica Chimica Acta*.
51. Sun, Y., Dong, Y., Wang, L., Xie, H., Li, B., Chang, C., & Wang, F. S. (2020). Characteristics and prognostic factors of disease severity in patients with COVID-19: The Beijing experience. *Journal of Autoimmunity*, 102473.
52. Piva, S., Filippini, M., Turla, F., Cattaneo, S., Margola, A., De Fulviis, S., ... & Erbici, G. (2020). Clinical presentation and initial management critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Brescia, Italy. *Journal of Critical Care*.
53. Meng, Y., Wu, P., Lu, W., Liu, K., Ma, K., Huang, L., ... & Ding, W. (2020). Sex-specific clinical characteristics and prognosis of coronavirus disease-19 infection in Wuhan, China: A retrospective study of 168 severe patients. *PLoS pathogens*, 16(4), e1008520.
54. Yanli Liu, Wenwu Sun, Yanan Guo, Liangkai Chen, Lijuan Zhang, Su Zhao, Ding Long & Li Yu (2020) Association between platelet parameters and mortality in coronavirus disease 2019: Retrospective cohort study, Platelets, DOI: 10.1080/09537104.2020.1754383
55. Zhou, Y., Han, T., Chen, J., Hou, C., Hua, L., He, S., ... & Zhao, C. (2020). Clinical and Autoimmune Characteristics of Severe and Critical Cases with COVID-19. *Clinical and Translational Science*.
56. Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W., ... & Cookingham, J. (2020). Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. *Jama*.

eAppendix 1. Detailed search strategies used in this review

May 5th 2020

	Before deduplication	After deduplication*
Embase.com	654	652
PubMed	699	312
Medline Ovid	589	45
Cochrane Trials	18	18
Web-of-Science	222	118
Google Scholar**	200	146
WHO Covid-19 Database	48	11
Total	2430	1302

*1128 duplicate records have been removed

**Google Scholar: first 1500 according to relevance ranking

Other sources: searching bibliographies of core articles, forward citation tracking (Web of Science, Google scholar).

Limits: excluding animal studies.

Embase.com

('covid 19'/exp OR 'coronavirus disease 2019'/exp OR 'Middle East respiratory syndrome coronavirus'/exp OR 'severe acute respiratory syndrome coronavirus 2'/exp OR 'SARS-related coronavirus'/exp OR 'coronaviridae'/de OR 'coronavirinae'/exp OR 'coronavirus infection'/exp OR (coronavir* OR corona virus* OR covid OR nCoV OR '2019-novel Cov' OR 'pneumonia virus*' OR 'Severe Acute Respiratory Syndrome*' OR SARS OR 'Middle East Respiratory Syndrome*' OR MERS):ab,ti,kw) AND ('iron deficiency'/exp OR 'anemia'/exp OR 'transferrin'/de OR 'ferritin'/de OR 'iron binding protein'/exp OR 'erythropoietin'/de OR 'soluble transferrin receptor'/de OR 'hepcidin'/de OR 'haptoglobin'/de OR 'unsaturated iron binding capacity'/de OR 'erythrocyte'/exp OR 'erythrocyte protoporphyrin'/de OR 'erythrocyte parameters'/exp OR 'hematocrit'/de OR 'hemoglobin'/exp OR 'hemoglobin blood level'/de OR 'risk factor'/de OR 'clinical feature'/de OR (anemi* OR anaemi* OR iron OR 'red blood cell*' OR haematocrit OR hematocrit OR transferrin* OR serotransferrin* OR siderophilin OR isotransferrin* OR apoferritin OR ferritin* OR isoferritin* OR immunoferritin* OR mycoferritin* OR proteoferrin* OR sanifer OR unifer OR erythropoieti* OR hematopoie* OR hemopoie* OR haematopoie* OR haemopoie* OR hepcidin* OR haptoglobin* OR UIBC OR (('free erythrocyte' OR normocyte OR 'red blood cell' OR 'red cell') NEAR/2 (protoporphyrin*)) OR erythrocyte* OR hemoglobin* OR haemoglobin* OR hemoglobulin* OR haemoglobulin* OR ferrohaemoglobin* OR ferrohemoglobin* OR 'risk factor*' OR ((clinical) NEAR/3

(characteristic* OR feature* OR predictor*)):ab,ti,kw) NOT ([animals]/lim NOT [humans]/lim) NOT ([Conference Abstract]/lim OR [Letter]/lim OR [Note]/lim OR [Editorial]/lim) AND [2019-3000]/py

PubMed

("Coronavirus"[Mesh] OR "Coronavirus Infections"[Mesh] OR "COVID-19" [Supplementary Concept] OR coronavir*[tiab] OR "corona virus*" [tiab] OR covid[tiab] OR nCoV[tiab] OR 2019-novel Cov OR pneumonia virus* OR "Severe Acute Respiratory Syndrome*" [tiab] OR SARS[tiab] OR "Middle East Respiratory Syndrome*" [tiab] OR MERS[tiab]) AND ("Anemia"[Mesh] OR "Transferrin"[Mesh] OR "Ferritins"[Mesh] OR "Erythropoietin"[Mesh] OR "Receptors, Transferrin"[Mesh] OR "Hepcidins"[Mesh] OR "Haptoglobins"[Mesh] OR "Erythrocytes"[Mesh] OR "Iron-Binding Proteins"[Mesh] OR "Hematocrit"[Mesh] OR "Hemoglobins"[Mesh] OR "Risk Factors"[Mesh] OR anemi*[tiab] OR anaemi*[tiab] OR iron[tiab] OR red blood cell*[tiab] OR haematocrit OR hematocrit OR transferrin*[tiab] OR serotransferrin*[tiab] OR siderophilin*[tiab] OR isotransferrin*[tiab] OR apoferritin*[tiab] OR ferritin*[tiab] OR isoferritin*[tiab] OR immunoferritin* OR mycoferritin* OR proteoferrin* OR sanifer OR unifer OR erythropoie*[tiab] OR hematopoie*[tiab] OR hemopoie*[tiab] OR haematopoie*[tiab] OR haemopoie*[tiab] OR hepcidin*[tiab] OR haptoglobin*[tiab] OR UIBC[tiab] OR (("free erythrocyte"[tiab] OR normocyte[tiab] OR "red blood cell" [tiab] OR "red cell" [tiab])) AND (protoporphyrin*[tiab])) OR erythrocyte*[tiab] OR hemoglobin*[tiab] OR haemoglobin*[tiab] OR hemoglobulin*[tiab] OR haemoglobulin*[tiab] OR ferrohaemoglobin*[tiab] OR ferrohemoglobin*[tiab] OR "risk factor*" [tiab] OR ((clinical[tiab]) AND (characteristic*[tiab] OR feature*[tiab] OR predictor*[tiab]))) NOT (animals[mh] NOT humans[mh]) NOT (letter[pt] OR news[pt] OR comment[pt] OR editorial[pt] OR congresses[pt] OR abstracts[pt]) AND 2019 : 3000 [dp]

[dp] = Publication date

Medline Ovid

(*Covid-19 Expert Search limit for Ovid MEDLINE) AND (exp anemia/ OR transferrin/ OR exp ferritins/ OR exp erythropoietin/ OR exp Receptors, Transferrin/ OR hepcidins/ OR haptoglobins/ OR unsaturated iron binding capacity/ OR exp erythrocytes/ OR exp Iron-Binding Proteins/ OR Hematocrit/ OR exp hemoglobins/ OR risk factors/ OR (anemi* OR anaemi* OR iron OR red blood cell* OR haematocrit OR haematocrit OR transferrin* OR serotransferrin* OR siderophilin OR isotransferrin* OR apoferritin OR ferritin* OR isoferritin* OR immunoferritin* OR mycoferritin* OR proteoferrin* OR sanifer OR unifer OR erythropoie* OR hematopoie* OR hemopoie* OR haematopoie* OR haemopoie* OR hepcidin* OR haptoglobin* OR UIBC OR ((free erythrocyte OR normocyte OR red blood cell OR red cell) ADJ2 (protoporphyrin*)) OR erythrocyte* OR hemoglobin* OR haemoglobin* OR hemoglobulin* OR haemoglobulin* OR ferrohaemoglobin* OR ferrohemoglobin* OR risk factor* OR ((clinical) ADJ3 (characteristic* OR feature* OR predictor*))).ab,ti,kw) NOT (exp animals/ NOT humans/) NOT (letter OR news OR comment* OR editorial* OR congres* OR abstract*).pt.

*<http://tools.ovid.com/coronavirus> : Wolters Kluwer, Expert Search Strategies COVID-19,

Ovid MEDLINE(R) All 1946 to present

Cochrane Central Register of Controlled Trials (Issue 5 of 12, May 2020)

((coronavir* OR corona NEXT virus* OR covid OR nCoV OR "2019-novel Cov" OR "pneumonia virus" OR "Severe Acute Respiratory Syndrome" OR SARS OR "Middle East Respiratory Syndrome" OR MERS):ab,ti,kw) AND ((anemi* OR anaemi* OR iron OR red-blood-cell* OR haematocrit OR haematocrit OR transferrin* OR serotransferrin* OR siderophilin OR isotransferrin* OR apoferritin OR ferritin* OR isoferritin* OR immunoferritin* OR mycoferritin* OR proteoferrin* OR sanifer OR unifer OR erythropoie* OR hematopoie* OR hemopoie* OR haematopoie* OR haemopoie* OR hepcidin* OR haptoglobin* OR UIBC OR ("free erythrocyte" OR normocyte OR "red blood cell" OR "red cell") NEAR/2 (protoporphyrin*)) OR erythrocyte* OR hemoglobin* OR haemoglobin* OR hemoglobulin* OR haemoglobulin* OR ferrohaemoglobin* OR ferrohemin* OR risk NEXT factor* OR ((clinical) NEAR/3 (characteristic* OR feature* OR predictor*)):ab,ti,kw)

Date range: 2019-2020

Web of Science Core Collection

TS=(((coronavir* OR "corona virus*" OR covid OR nCoV OR "2019-novel Cov" OR "pneumonia virus*" OR "Severe Acute Respiratory Syndrome" OR SARS OR "Middle East Respiratory Syndrome" OR MERS)) AND ((anemi* OR anaemi* OR iron OR "red blood cell*" OR haematocrit OR hematocrit OR transferrin OR transferrins OR serotransferrin* OR siderophilin OR isotransferrin* OR apoferritin OR ferritin* OR isoferritin* OR immunoferritin* OR mycoferritin* OR proteoferrin* OR sanifer OR unifer OR erythropoie* OR hematopoie* OR hemopoie* OR haematopoie* OR haemopoie* OR hepcidin* OR haptoglobin* OR UIBC OR ("free erythrocyte" OR normocyte OR "red blood cell" OR "red cell") NEAR/2 (protoporphyrin*)) OR erythrocyte* OR hemoglobin* OR haemoglobin* OR hemoglobulin* OR haemoglobulin* OR ferrohaemoglobin* OR ferrohemin* OR "risk factor*" OR ((clinical) NEAR/3 (characteristic* OR feature* OR predictor*)))) AND DT=(article)

PUBLICATION YEARS: (2020 OR 2019)

Google scholar first 200 results

covid|coronavirus|sars|cov
anemia|anaemia|transferrin|ferritin|iron|erythropoietin|hemoglobin|haemoglobin|erythrocyte|erythrocytes|hepcidin|haptoglobin
